This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease


Sato, Y., Honda, Y., Iwamoto, J., Amano, N.


Journal Of Musculoskeletal & Neuronal Interactions, Volume: 13, No.: 3, Pages.: 346-352

Year of Publication



Objectives: Minodronate is a nitrogen-containing bisphosphonate that is commercially available for the treatment of osteoporosis in Japan. Preclinical studies demonstrated that minodronate is at least 10 times more potent than alendronate in inhibiting bone resorption in vivo. A high incidence of fractures, particularly of the hip, represents an important problem in Alzheimer disease (AD) patients who are prone to falls and may have osteoporosis.; Methods: A total of 256 elderly patients with AD were assigned to daily treatment with 1.0 mg of minodronate or a daily treatment with risedronate combined with daily 1000 IU ergocalciferol and 1200 mg elemental calcium, and followed up for 12 months.; Results: At baseline, patients of both groups showed low 25-hydroxyvitamin D with compensatory hyperparathyroidism. Non-vertebral fractures occurred in 5 patients in the minodronate group and 7 patients in the risedronate group (5 hip fractures; one fracture each at the distal forearm and pelvis). There was no difference in risk of hip fracture between the two groups (p=.70; odds ratio=0.8).; Conclusions: The study medications were well tolerated with relatively few adverse events and were equivalent in reducing the risk of a fracture in elderly patients with AD.;


accidental falls, aged, alzheimer disease, analogs derivatives, body mass index, bone, bone density, bone density conservation agents, complications, density, diphosphonates, drug effects, drug therapy, drugs, etidronic acid, fall, female, fractures bone, humans, imidazoles, improving, minodronate, or, osteoporosis, prevention, prevention & control, risedronate, therapeutic use, using

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes

Physical Health, Prevention and/or management of co-morbidities

Type of Interventions

Treatment/prevention of co-morbidities or additional risks


Fall Prevention, Other